Detalles de la búsqueda
1.
Translational approach from preclinical to clinical: comparison of dose finding methods of a new Bcl2 inhibitor using PK-PD modeling and interspecies extrapolation.
Invest New Drugs
; 38(6): 1796-1806, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32451663
2.
Prediction of Human Nonlinear Pharmacokinetics of a New Bcl-2 Inhibitor Using PBPK Modeling and Interspecies Extrapolation Strategy.
Drug Metab Dispos
; 47(6): 648-656, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30940629
3.
Tumor Growth Inhibition Modelling Based on Receptor Occupancy and Biomarker Activity of a New Bcl-2 Inhibitor in Mice.
J Pharmacol Exp Ther
; 367(3): 414-424, 2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30228112
4.
Oral drug absorption in pediatrics: the intestinal wall, its developmental changes and current tools for predictions.
Biopharm Drug Dispos
; 38(3): 209-230, 2017 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-27976409
5.
Model-based approaches for ivabradine development in paediatric population, part I: study preparation assessment.
J Pharmacokinet Pharmacodyn
; 43(1): 13-27, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26563503
6.
A physiologically based modeling strategy during preclinical CNS drug development.
Mol Pharm
; 11(3): 836-48, 2014 Mar 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-24446829
7.
Comparing translational population-PBPK modelling of brain microdialysis with bottom-up prediction of brain-to-plasma distribution in rat and human.
Biopharm Drug Dispos
; 35(8): 485-99, 2014 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-25044007
8.
A New Version of the Tissue Composition-Based Model for Improving the Mechanism-Based Prediction of Volume of Distribution at Steady-State for Neutral Drugs.
J Pharm Sci
; 113(1): 118-130, 2024 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37634869
9.
Physiologically based pharmacokinetic (PBPK) modelling tools: how to fit with our needs?
Biopharm Drug Dispos
; 33(2): 55-71, 2012 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-22228149
10.
Effect of variations in the amounts of P-glycoprotein (ABCB1), BCRP (ABCG2) and CYP3A4 along the human small intestine on PBPK models for predicting intestinal first pass.
Mol Pharm
; 7(5): 1596-607, 2010 Oct 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-20604570
11.
Unraveling the mechanism and the risk behind seizure liability of lead compounds in a neuroscience project.
J Pharmacol Toxicol Methods
; 104: 106874, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32446729
12.
Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium Perspective.
Clin Pharmacol Ther
; 104(1): 88-110, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29315504
13.
Physiologically based pharmacokinetic modelling of drug penetration across the blood-brain barrier--towards a mechanistic IVIVE-based approach.
AAPS J
; 15(4): 913-32, 2013 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-23784110
14.
S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab.
Mol Cancer Ther
; 12(9): 1749-62, 2013 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-23804704
15.
Development of a physiologically based pharmacokinetic model for the rat central nervous system and determination of an in vitro-in vivo scaling methodology for the blood-brain barrier permeability of two transporter substrates, morphine and oxycodone.
J Pharm Sci
; 101(11): 4277-92, 2012 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-22864977
16.
Quantitative mass spectrometry imaging of propranolol and olanzapine using tissue extinction calculation as normalization factor.
J Proteomics
; 75(16): 4952-4961, 2012 Aug 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-22842155
17.
Predictions of metabolic drug-drug interactions using physiologically based modelling: Two cytochrome P450 3A4 substrates coadministered with ketoconazole or verapamil.
Clin Pharmacokinet
; 49(4): 239-58, 2010 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-20214408
18.
Drug-drug interaction predictions with PBPK models and optimal multiresponse sampling time designs: application to midazolam and a phase I compound. Part 1: comparison of uniresponse and multiresponse designs using PopDes.
J Pharmacokinet Pharmacodyn
; 35(6): 635-59, 2008 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-19130188
19.
Drug-drug interaction predictions with PBPK models and optimal multiresponse sampling time designs: application to midazolam and a phase I compound. Part 2: clinical trial results.
J Pharmacokinet Pharmacodyn
; 35(6): 661-81, 2008 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-19130187
Resultados
1 -
19
de 19
1
Próxima >
>>